Research article · 15 Apr 2026
Conference abstractPublished 23 Nov 2022
Crescentic IgA nephropathy presenting with erythrocytosis in a 70-year-old male: A case report
Chong Hua Hospital, Philippines
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Erythrocytosis is defined as an increase in RBCs relative to the blood volume or an increase in red cell mass. Rarely, it can be associated with renal manifestations, including IgA nephropathy, FSGS, MPGN, and RPGN. IgA nephropathy is the most common of which and usually occurs in males. Despite being the most common cause of primary glomerular disease worldwide, IgA Nephropathy exhibits marked heterogeneity in its clinical and pathological features. The pathophysiologic correlation between IgA nephropathy and Erythrocytosis is complex. It can be briefly explained by the formation of vascular microthrombi and glomerular capillary occlusion, which reduces GFR and tissue ischemia. Clinical presentation: The patient is a 70-year-old male with nephrotic range proteinuria and erythrocytosis. Further probing narrowed down the diagnosis between smoker’s polycythemia, polycythemia vera, and secondary to glomerulonephritis. During admission, the patient underwent sessions of therapeutic phlebotomy, with serial monitoring of CBC and creatinine. Renal biopsy showed crescentic IgA nephropathy. Optimization of kidney protective measures was done, which include: BP control, RAAS blockade, lifestyle modification, and addressing cardiovascular risks. Conclusion: To the best knowledge, there have been 24 cases of polycythemia associated with the renal disease described so far, and out of them, only ten have been associated with IgAN. The pathophysiologic relationship between erythrocytosis and IgA Nephropathy remains unclear. However, the hypercoagulable state and circulatory disturbances that ensue may contribute to the disease progression. Given the current uncertainty over the safety and efficacy of existing immunosuppressive treatment choices in IgA Nephropathy, all patients who remain at high risk of progressive CKD despite maximal supportive care should be offered immunosuppressive drugs with a detailed discussion of the risks and benefits, and the opportunity to take part in a clinical trial if feasible. Understanding their pathophysiologic process despite their atypical incidence may pave further advances in the management and attenuation of worsening renal function. Keywords: IgA Nephropathy, Erythrocytosis, Polycythemia.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Melvy June Balasa”
